Assertio Holdings, Inc. Announces Leadership Transition
04 January 2024 - 12:59AM
Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ:
ASRT), a specialty pharmaceutical company that acquires,
commercializes and develops safe and effective therapies that make
a difference in the lives of patients, announced today that Dan
Peisert is stepping down as the Company’s Chief Executive Officer.
The Board has appointed Heather Mason, currently an independent
director of the Company and Chair of its Nominating and Corporate
Governance Committee, to serve as interim CEO as the Company
conducts a search for a permanent chief executive.
Peter Staple, Chairman of the Assertio Board of Directors, said,
“On behalf of the Board, I would like to express our appreciation
to Dan for his contributions to the growth and transformation of
Assertio in his roles as CEO, and earlier as CFO.”
Ms. Mason has served as a member of the Assertio board since
2019 and brings deep experience as a leader in the pharmaceutical
and healthcare industry with a strong track record in successful
commercial execution. She has held several senior leadership
positions at Abbott Laboratories, including Executive Vice
President, Nutrition, Senior Vice President of Diabetes Care, Vice
President of Specialty Pharmaceuticals and Vice President,
International Marketing, and played a key role in Abbott’s launch
and commercialization of Humira®, one of the most successful
pharmaceutical products in history.
“I am committed to Assertio and its employees and stakeholders,
and its future success,” Ms. Mason said. “I will work to ensure
that we are best positioned to maximize the opportunities in front
of us, and to ensure a smooth leadership transition as we bring in
a CEO to lead the Company into the next phase of our business.”
About Assertio
Assertio is a specialty pharmaceutical company that acquires,
commercializes and develops safe and effective therapies that make
a difference in the lives of patients. Utilizing a proprietary
digital-focused commercialization approach we can promote products
across multiple therapeutic categories. We strive to lead by
example, embrace change, and make a positive impact in our
community while creating better experiences for our employees,
partners and shareholders. To learn more about Assertio visit
www.assertiotx.com.
Forward Looking Statements
Statements in this communication that are not historical facts
are forward-looking statements that reflect Assertio’s current
expectations, assumptions and estimates of future performance and
economic conditions. These forward-looking statements are made in
reliance on the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements relate to, among other things, future events or the
future performance or operations of Assertio, including risks
related to the potential disruption of management time from ongoing
business operations due to the leadership transition; our ability
to successfully recruit a permanent CEO and the timing thereof; our
ability to attract and retain other key management and operating
personnel; and our ability to realize the benefits from our
operating model, successfully integrate new assets and explore new
business development initiatives. All statements other than
historical facts may be forward-looking statements and can be
identified by words such as “anticipate,” “believe,” “could,”
“design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,”
“imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,”
“plan,” “position,” “potential,” “predict,” “project,”
“prospective,” “pursue,” “seek,” “should,” “strategy,” “target,”
“would,” “will,” “aim” or other similar expressions that convey the
uncertainty of future events or outcomes and are used to identify
forward-looking statements. Such forward-looking statements are not
guarantees of future performance and are subject to risks,
uncertainties and other factors, some of which are beyond the
control of Assertio, including the risks described in Assertio’s
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed
with the U.S. Securities and Exchange Commission (“SEC”) and in
other filings Assertio makes with the SEC from time to time.
Investors and potential investors are urged not to place undue
reliance on forward-looking statements in this communication, which
speak only as of this date. While Assertio may elect to update
these forward-looking statements at some point in the future, it
specifically disclaims any obligation to update or revise any
forward-looking-statements contained in this press release whether
as a result of new information or future events, except as may be
required by applicable law.
Investor Contact:
Matt KrepsManaging DirectorDarrow AssociatesAustin, TX M:
214-597-8200mkreps@darrowir.com
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Apr 2024 to May 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From May 2023 to May 2024